Exelixis gains
Last week, the biotech sector was in focus, with regular pipeline and regulatory updates. Vanda Pharmaceuticals Inc. VNDA was ...
US-based biotechnology companies Exelixis and MSD have partnered to assess the potential of combining their respective cancer ...
A federal judge in Delaware has ruled in favor of Exelixis in its Cabometyx patent fight with MSN Laboratories, effectively ...
Zacks.com on MSN1d
Exelixis (EXEL) Soars 8.6%: Is Further Upside Left in the Stock?Exelixis EXEL shares ended the last trading session 8.6% higher at $28.50. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This ...
Leerink Partners analyst Andrew Berens has maintained their neutral stance on EXEL stock, giving a Hold rating today. Andrew Berens has given ...
Shares of Exelixis, Inc. EXEL have risen 20.7% in the past three months compared with the industry’s growth of 6.3%. The ...
Zacks.com on MSN2d
Exelixis, MRK Collaborate for Combination Studies on HNSCC and RCCExelixis, Inc. EXEL entered into a clinical development collaboration agreement with pharma giant Merck MRK to advance the ...
Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Stephen Willey ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback